This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. Also known as 2019-nCoV, the virus causes COVID-19. The sample was isolated from a patient in the U.S. Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. (NIAID-RML via AP)

This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. Also known as 2019-nCoV, the virus causes COVID-19. The sample was isolated from a patient in the U.S. Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. (NIAID-RML via AP)

Behind the scenes, scientists prep for COVID-19 vaccine test

Work on an experimental vaccine is underway

A team of scientists jostled for a view of the lab dish, staring impatiently for the first clue that an experimental vaccine against the new coronavirus just might work.

After weeks of round-the-clock research at the National Institutes of Health, it was time for a key test. If the vaccine revs up the immune system, the samples in that dish — blood drawn from immunized mice — would change colour.

Minutes ticked by, and finally they started glowing blue.

“Especially at moments like this, everyone crowds around,” said Kizzmekia Corbett, an NIH research fellow leading the vaccine development. When her team sent word of the positive results, “it was absolutely amazing.”

Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. Importantly, they’re pursuing different types of vaccines — shots developed from new technologies that not only are faster to make than traditional inoculations but might prove more potent. Some researchers even aim for temporary vaccines, such as shots that might guard people’s health a month or two at a time while longer-lasting protection is developed.

“Until we test them in humans we have absolutely no idea what the immune response will be,” cautioned vaccine expert Dr. Judith O’Donnell, infectious disease chief at Penn Presbyterian Medical Center. “Having a lot of different vaccines — with a lot of different theories behind the science of generating immunity — all on a parallel track really ultimately gives us the best chance of getting something successful.”

First-step testing in small numbers of young, healthy volunteers is set to start soon. There’s no chance participants could get infected from the shots, because they don’t contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests of whether they protect.

First in line is the Kaiser Permanente Washington Health Research Institute in Seattle. It is preparing to test 45 volunteers with different doses of shots co-developed by NIH and Moderna Inc.

Next, Inovio Pharmaceuticals aims to begin safety tests of its vaccine candidate next month in a few dozen volunteers at the University of Pennsylvania and a testing centre in Kansas City, Missouri, followed by a similar study in China and South Korea.

Even if initial safety tests go well, “you’re talking about a year to a year and a half” before any vaccine could be ready for widespread use, stressed Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases.

That still would be a record-setting pace. But manufacturers know the wait — required because it takes additional studies of thousands of people to tell if a vaccine truly protects and does no harm — is hard for a frightened public.

“I can really genuinely understand everybody’s frustration and maybe even confusion,” said Kate Broderick, Inovio’s research and development chief. “You can do everything as fast as possible, but you can’t circumvent some of these vital processes.”

READ MORE: COVID-19 stricken Grand Princess with 237 Canadians on board cleared to dock in California

___

BEHIND-THE-SCENES IN NIH’S LAB

The new coronavirus is studded with a protein aptly named “spike” that lets the virus burrow into human cells. Block that protein, and people won’t get infected. That makes “spike” the target of most vaccine research.

Not so long ago, scientists would have had to grow the virus itself to create a vaccine. The NIH is using a new method that skips that step. Researchers instead copy the section of the virus’ genetic code that contains the instructions for cells to create the spike protein, and let the body become a mini-factory.

Inject a vaccine containing that code, called messenger RNA or mRNA, and people’s cells produce some harmless spike protein. Their immune system spots the foreign protein and makes antibodies to attack it. The body would then be primed to react quickly if the real virus ever comes along.

Corbett’s team had a head start. Because they’d spent years trying to develop a vaccine against MERS, a cousin of the new virus, they knew how to make spike proteins stable enough for immunization, and sent that key ingredient to Moderna to brew up doses.

How to tell it’s a good candidate to test in people?

Corbett’s team grew spike protein in the lab — lots of it — and stored it frozen in vials. Then with the first research doses of vaccine Moderna dubbed “mRNA-1273,” the NIH researchers immunized dozens of mice. Days later, they started collecting blood samples to check if the mice were producing antibodies against that all-important spike protein. One early test: Mix the mouse samples with thawed spike protein and various colour-eliciting trackers, and if antibodies are present, they bind to the protein and glow.

Corbett says the work couldn’t have moved so quickly had it not been for years of behind-the-scenes lab testing of a possible MERS vaccine that works the same way.

“I think about it a lot, how many of the little experimental questions we did not have to belabour” this time around, she said. When she saw the first promising mouse tests, “I felt like there was a beginning of all of this coming full circle.”

___

INOVIO’S APPROACH

Inovio’s approach is similar — again using genetic code, in this case packaged inside a piece of synthetic DNA that acts as the vaccine. One advantage Broderick cites for a DNA approach is that unlike many types of vaccines, it may not need refrigeration.

A MERS vaccine that Inovio designed the same way passed initial safety studies in people, paving the way for testing the new COVID-19 vaccine candidate. Inovio is doing similar animal testing to look for presumably protective antibodies.

While it gets ready for human safety tests, Inovio also is prepping for another piece of evidence — what’s called a challenge study. Vaccinated animals will be put in a special high-containment lab and exposed to the new coronavirus to see if they get infected or not.

___

PLACEHOLDER VACCINES?

Regeneron Pharmaceuticals is exploring a different approach: simply injecting people with coronavirus-fighting antibodies instead of teaching the body to make its own. This method could provide temporary protection against infection or work as a treatment for someone already infected.

Regeneron vaccinated mice genetically engineered to make human antibodies. From small blood samples, researchers culled hundreds of different antibodies, and now they’re teasing out which seem most potent against that notorious spike protein, said Christos Kyratsous, Regeneron’s chief of infectious disease research.

Regeneron developed this “monoclonal antibody” approach as a life-saving treatment for Ebola. Last year, it performed a successful safety test of experimental antibodies designed to fight MERS.

The difference between using antibodies as a treatment or a vaccine? Low-dose shots in the arm every few months might give enough antibodies to temporarily ward off infection, while treatment likely would require far higher doses delivered intravenously, Kyratsous said. Regeneron is pursuing both, and hopes to begin first-step safety testing in early summer.

“The antibodies are the same,” he said. “We would like to have an antibody that is as flexible in administration as possible.”

Whichever of these approaches, or others in the pipeline, pan out, NIH’s Corbett said scientists one day hope to have vaccines on the shelf that could be used against entire families of viruses. One frustration when scientists have to start from scratch is that outbreaks too often are waning by the time vaccine candidates are ready for widespread testing.

“This is the fastest we have gone,” Fauci said of the NIH’s vaccine candidate, although he warned it might not be fast enough.

Still, he called it “quite conceivable” that COVID-19 “will go beyond just a season, and come back and recycle next year. In that case, we hope to have a vaccine.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Lauran Neergaard, The Associated Press


Like us on Facebook and follow us on Twitter.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Anvy Technologies CEO Victor Nicolov displays his company’s innovative garbage disposal device, the Sepura. (Courtesy of Anvy Technologies)
Goodbye garburator, this Victoria company has a clean composting solution

Sepura has made Times Magazine’s ‘100 Best Inventions of 2020’ for its hassle-free functioning

Merchants along Fort Street are hosting the Winter Wander holiday shopping event Dec. 5. (Don Descoteau/News Staff)
Wander along Fort Street for a total holiday shopping experience

Merchants featuring discounts, special offerings; community event set for Dec. 5

Sweetpal Chauhan, operator of several Shell Gas stations in Greater Victoria, donated 100 jackets and 100 sleeping bags to Our Place on Friday. (Kendra Crighton/News Staff)
PHOTOS: Victoria businessman donates 100 jackets, 100 sleeping bags to Our Place

Warm jackets, sleeping bags can mean the ‘difference between life and death’

Nikita, a four-year-old German Shepherd that was attacked by a buck in a backyard in Esquimalt Sunday is lucky the injury wasn't more severe. (Photo contributed by Suzette Goldsworthy)
Esquimalt dog owner issues alert after deer injures German shepherd

Nikita needed stitches after an early morning encounter

The Victoria Police Department headquarters. (Black Press Media file photo)
Investigation launched into man’s death after arrest in Victoria

IIO investigation to determine if police actions or inaction played a role in the man’s death

People wearing face masks to help curb the spread of COVID-19 cross a street in downtown Vancouver, on Sunday, November 22, 2020. The use of masks is mandatory in indoor public and retail spaces in the province. THE CANADIAN PRESS/Darryl Dyck
B.C. reports 17 COVID deaths, 1,933 new cases as hospitalizations surge over the weekend

There are 277 people in hospital, of whom 59 are in ICU or critical care

An aerial shot of Cedar Valley Lodge this past August, LNG Canada’s newest accommodation for workers at the project site in Kitimat. This is where several employees are isolating after a COVID-19 outbreak was declared last Thursday (Nov. 19). (Photo courtesy of LNG Canada)
Forty-one positive COVID-19 cases associated with the LNG Canada site outbreak in Kitimat

Thirty-four of the 41 cases remain active, according to Northern Health

7-year-old Mackenzie Hodge from Penticton sent a hand-written letter to premiere John Horgan asking if she’d be able to see her elf, Ralph under the new coronavirus restrictions. (John Horgan / Twitter)
Elf on the shelf an acceptable house guest, B.C. premier tells Penticton girl

A 7-year-old from Penticton penned a letter asking if she’d be allowed to see her elf this year

Workers arrive at the Lynn Valley Care Centre seniors home, in North Vancouver, B.C., on Saturday, March 14, 2020. It was the site of Canada’s first COVID-19 outbreak in a long-term care facility. THE CANADIAN PRESS/Darryl Dyck
Rapid tests ‘not a panacea’ for care homes, Dr. Bonnie Henry says

B.C. lacks capacity for daily tests of thousands of workers

(Delta Police Department photo)
Cannabis edibles found in Halloween bag lead B.C. police to illegal lab

Delta police arrested a man and a woman while executing a warrant at a residential property Nov. 20

A woman being arrested at a Kelowna Value Village after refusing to wear a mask on Nov. 22.(@Jules50278750/Twitter)
VIDEO: Woman arrested for refusing to wear mask at Kelowna Value Village

RCMP claims the woman was uncooperative with officers, striking them a number of times and screaming

B.C. Liberal MLA Shirley Bond questions NDP government ministers in the B.C. legislature, Feb. 19, 2020. (Hansard TV)
Cabinet veteran Shirley Bond chosen interim leader of B.C. Liberals

28-member opposition prepares for December legislature session

Motorists wait to enter a Fraser Health COVID-19 testing facility, in Surrey, B.C., on Monday, November 9, 2020. THE CANADIAN PRESS/Darryl Dyck
COVID-19: What do rising positivity rates mean for B.C.? It’s not entirely clear

Coronavirus cases are on the rise but the province has not unveiled clear thresholds for further measures

Most Read